---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-045998"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:33:19.789093+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# VYNE reports Q3 net loss $12.2M; VYN201 Phase 2b enrollment exceeds target, top-line mid-2025

## Summary
- Net loss of $12.2M ($0.29/sh) in Q3 2024 vs $6.6M ($2.01/sh) in Q3 2023, driven by higher R&D spend.
- Cash and marketable securities of $70.2M; expected to fund operations through end of 2025.
- VYN201 Phase 2b vitiligo trial enrollment exceeded target; fully enrolled Dec 2024, top-line mid-2025.
- VYN202 Phase 1a SAD data positive; MAD data expected Q4 2024. Plans for Phase 1b in psoriasis and RA.
- R&D expenses rose 208.9% to $10.2M due to advancing clinical trials.

## SEC filing metadata
- accession: 0001628280-24-045998
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000162828024045998/0001628280-24-045998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000162828024045998/mnlo-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-045998
- JSON: https://secwatch.observer/filing/0001628280-24-045998.json
- Plain text: https://secwatch.observer/filing/0001628280-24-045998.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.